These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1979129)
1. Fatal case of 2',3'-dideoxyinosine-associated pancreatitis. Bouvet E; Casalino E; Prevost MH; Vachon F Lancet; 1990 Dec; 336(8729):1515. PubMed ID: 1979129 [No Abstract] [Full Text] [Related]
2. Pancreatitis in AIDS patients treated with didanosine. Daniels M Am J Gastroenterol; 1993 Mar; 88(3):459-60. PubMed ID: 8438864 [No Abstract] [Full Text] [Related]
4. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Lai KK; Gang DL; Zawacki JK; Cooley TP Ann Intern Med; 1991 Aug; 115(4):283-4. PubMed ID: 1906693 [No Abstract] [Full Text] [Related]
5. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine. Grasela TH; Walawander CA; Beltangady M; Knupp CA; Martin RR; Dunkle LM; Barbhaiya RH; Pittman KA; Dolin R; Valentine FT J Infect Dis; 1994 Jun; 169(6):1250-5. PubMed ID: 8195601 [TBL] [Abstract][Full Text] [Related]
6. Acute pancreatitis in a prisoner with AIDS. Bugs or drugs? Cina SJ; Conradi SE Am J Forensic Med Pathol; 1994 Mar; 15(1):28-31. PubMed ID: 8166111 [TBL] [Abstract][Full Text] [Related]
7. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Maxson CJ; Greenfield SM; Turner JL Am J Gastroenterol; 1992 Jun; 87(6):708-13. PubMed ID: 1590305 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189 [TBL] [Abstract][Full Text] [Related]
9. Didanosine-induced hypertriglyceridemia. Tal A; Dall L Am J Med; 1993 Aug; 95(2):247. PubMed ID: 8356993 [No Abstract] [Full Text] [Related]
10. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724 [TBL] [Abstract][Full Text] [Related]
11. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965 [TBL] [Abstract][Full Text] [Related]
12. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726 [TBL] [Abstract][Full Text] [Related]
13. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. Seidlin M; Lambert JS; Dolin R; Valentine FT AIDS; 1992 Aug; 6(8):831-5. PubMed ID: 1418780 [TBL] [Abstract][Full Text] [Related]
14. New drug therapy for patients with HIV. Nursing implications in the administration of 2',3'-dideoxyinosine (ddI). Shay LE; Thomas RV; Wyvill KM; Adamo DO; Jenkins JF Cancer Nurs; 1990 Oct; 13(5):269-77. PubMed ID: 2123127 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center. Valentine FT; Seidlin M; Hochster H; Laverty M Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725 [TBL] [Abstract][Full Text] [Related]
16. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419 [TBL] [Abstract][Full Text] [Related]
17. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528 [TBL] [Abstract][Full Text] [Related]
18. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily. Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727 [TBL] [Abstract][Full Text] [Related]
19. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971 [TBL] [Abstract][Full Text] [Related]